INSM vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 31, 2026

INSM

42.2
AI Score
VS
INSM Wins

MRNA

35.8
AI Score

Investment Advisor Scores

INSM

42score
Recommendation
HOLD

MRNA

36score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric INSM MRNA Winner
Revenue 731.45M 534.00M INSM
Net Income -176.81M -2.13B INSM
Net Margin -24.2% -397.9% INSM
Operating Income -154.87M -2.20B INSM
ROE -23.3% -31.4% INSM
ROA -8.4% -19.4% INSM
Total Assets 2.10B 10.96B MRNA
Cash 544.76M 1.72B MRNA
Debt/Equity 0.72 0.09 MRNA
Current Ratio 3.72 2.29 INSM
Free Cash Flow -321.31M -1.25B INSM

Relative Price Performance (Last 90 Days)

INSM 1M: +23.5% · 3M: +14.9% MRNA 1M: +156.0% · 3M: +204.7%

Current Technical Phase

INSM

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (8.7% over 20 days), RSI 52

RSI (14): 52.4 · Price: $121.82

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (33.8% over 20 days), RSI 64

RSI (14): 64.1 · Price: $140.34

Fundamentals Snapshot

Metric INSM MRNA
Market Cap
Forward P/E 151.9 -28.2
Trailing P/E
Revenue (TTM)
Revenue Growth 3.0% 0.0%
Gross Margin 0.8% -0.7%
Operating Margin -0.2% -5.6%
EPS -4.02 -7.71
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, INSM is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.